[A20-84] Darolutamide (prostate cancer) - Addendum to Commission A20-43

Last updated 15.10.2020

Project no.:
A20-84

Commission:
Commission awarded on 08.09.2020 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Adults with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease

Result of dossier assessment:

Conclusion of dossier assessment A20-43 unchanged

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

15.10.2020 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.